Immunocore Holdings plc
HealthcareNASDAQ:IMCR · NASDAQ Global Select
+$0.34 today
Vol 0.28M · Avg 0.40M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-6.9%
avg -85.3%
ROIC
-4.1%
avg -27.8%
ROA
-2.5%
avg -18.5%
Analysis
ROA is currently the strongest return metric at -2.5% versus its period average of -18.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Bahija Jallal | Chief Executive Officer & Executive Director | $1.49M | — | 65 | $12,343.00 | 0.02% |
Travis A. Coy | Chief Financial Officer, Executive Vice President & Head of Corporate Development | $871,220.00 | — | 46 | $95,637.00 | 0.19% |
Tina Leger | Executive Vice President & Chief Human Resources Officer | $578,070.00 | — | 58 | $1,119.00 | <0.01% |
Sébastien Desprez | Vice President of Communications | — | — | — | — | — |
Kripa Ram | Executive VP & Chief Operating Officer | — | — | 63 | — | — |
Clayton Robertson | Head of Investor Relations | — | — | — | — | — |
John Goll | SVP, Finance & Chief Accounting Officer | — | — | — | $27,492.00 | 0.05% |
John Trainer | SVP & Chief Operating Officer | — | — | 52 | $27,492.00 | 0.05% |
Annelise Vuidepot | Senior Vice President, Chief Technology Officer and Research & UK Site Lead | — | — | — | — | — |
Debra Nielsen | VP & Chief of Staff | — | — | — | — | — |
Elizabeth Varki Jobes | Chief Compliance Officer | — | — | 59 | — | — |
Lily Margaret Hepworth | Executive Vice President, General Counsel & Company Secretary | — | — | 43 | — | — |
Sean D. Buckley | Vice President & Chief Information Officer | — | — | 43 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
17
$10.45M
Net Sentiment
$10.45M
Net selling
Most Active
Berman David M
14 transactions
1–10 of 17
Analysis
Insiders reported 0 buys worth $0.00 and 17 sells worth $10.45M over the last 12 months. That adds up to net selling of $10.45M. Berman David M was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A3 analysts |
| Revenue | N/A | N/A | +31.3% | +39.0% (13yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +31.3% over three years. Forward estimates point to Revenue at +39.0% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMY
$1.99B
Nuvation Bio Inc.
NYSE:NUVB
$1.71B
Sionna Therapeutics, Inc.
NASDAQ:SION
$1.62B
AbCellera Biologics Inc.
NASDAQ:ABCL
$1.60B
Biohaven Ltd.
NYSE:BHVN
$1.19B
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
$1.17B
MannKind Corporation
NASDAQ:MNKD
$1.13B
Janux Therapeutics, Inc.
NASDAQ:JANX
$826.95M
Who manages IMCR?
Immunocore Holdings plc (IMCR) lists 13 active executives. The top listed executive is Sébastien Desprez, Vice President of Communications.
Are IMCR insiders buying or selling?
Recent insider activity shows net selling of $35.37M.
Explore More
Continue the stock analysis
Jump to another research area for this company.